CD20

Acepodia Secures $100 Million Series D Financing to Advance

Retrieved on: 
星期二, 六月 6, 2023
ACC, Nobel Prize, Genetic engineering, Nobel Prize in Chemistry, Venture round, Cancer, CD20, Research, Click chemistry, Hematological Cancer Research Investment and Education Act, Patient, Non-Hodgkin lymphoma, Venture capital financing, Vaccine, Chemistry

ALAMEDA, Calif. and TAIPEI, June 6, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced a $100 million Series D financing led by Digital Mobile Venture with participation from additional existing investors. The funds will be used to progress the company's pipeline of enhanced cell therapies for solid tumors and hematologic cancers, including ACE1831 and ACE2016. ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma. ACE 2016 is an anti-EGFR armed allogeneic gamma delta 2 T-cell therapy targeting EGFR-expressing solid tumors.

Key Points: 
  • ACE1831 is an anti-CD20 armed allogeneic gamma delta 2 T-cell therapy currently being studied in a Phase 1 trial for patients with non-Hodgkin Lymphoma.
  • "This financing illustrates the confidence of Acepodia's current investors in our team, our mission, and our differentiated platform, and we are extremely grateful for their support," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia.
  • Acepodia has raised $259 million to date in venture capital financing, including a $109 million Series C round completed in December 2021.
  • Returning investors in the Series D included Digital Mobile Venture as the lead investor.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
星期一, 六月 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Retrieved on: 
星期三, 五月 31, 2023
Graft-versus-host disease, Antigen, TRAC, Euronext Growth, CD19, Lymphoid leukemia, CD20, Neoplasm, CD52, Bone marrow, CD22, Attention, PDX, CAR, Death, Cancer Immunology Research, Animal, Patient, Risk, Mantle cell lymphoma, Cancer, Research, Vaccine, Cellectis

To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.

Key Points: 
  • To address these challenges, Cellectis developed UCART20x22, its first allogeneic dual CAR T-cell product candidate targeting two validated antigens commonly expressed in B-cell malignancies, CD20 and CD22, and whose expression is preserved after CD19 CAR T-cell treatment.
  • Moreover, UCART20x22 is developed to be available off-the-shelf and to offer a solution for patients whose T-cells are not functional or for which autologous manufacturing fails.
  • UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house at Cellectis.
  • This article is available on Cancer Immunology Research website by clicking on this link: https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066....

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Retrieved on: 
星期三, 五月 31, 2023
Inflammation, Tissue, Rituximab, RA, IGM, CRS, CD20, Drug discovery, Immunoglobulin M, NHL, Pharmacokinetics, Lead, Autoimmunity, SLE, Incidence, Cytokine release syndrome, Patient, Autoimmune disease, Immune system, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, Food, Rheumatoid arthritis, Vaccine

The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.

Key Points: 
  • The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023.
  • “Over the last two decades, CD20 has become well-established as a therapeutic target in multiple autoimmune diseases.
  • In preclinical in vivo studies, imvotamab has demonstrated deep B cell depletion within tissues, where depletion of pathogenic immune cells may be critical to long-term clinical benefit in autoimmune diseases.
  • Imvotamab has also demonstrated in preclinical in vitro studies that it can be more effective in depleting B cells with low levels of CD20 expression as compared to rituximab.

Be Biopharma Study Shows First Demonstration of Rapid Engraftment of B Cells without Preconditioning in Non-Human Primates with Intact Immune Systems

Retrieved on: 
星期五, 五月 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Human, Gene, CD20, Engineering, National Heart, Lung, and Blood Institute, Bone marrow, PET, Therapure BioPharma Inc, Cell, PST, Lung, Plasma cell, Bangladesh Technical Education Board, NHLBI, Spleen, Patient, B cell, Annual general meeting, PET/CT, Liver, Chromium toxicity, NHP, Society, Vaccine

The study was designed to evaluate engraftment without preconditioning of ex vivo expanded NHP plasma cells.

Key Points: 
  • The study was designed to evaluate engraftment without preconditioning of ex vivo expanded NHP plasma cells.
  • Plasma cells are terminally differentiated B cells which can live for decades1 and have the capacity to secrete extremely high levels of protein2.
  • In two NHPs, B cells were collected, expanded, and differentiated into plasma cells.
  • Differentiation to plasma cells was demonstrated by loss of CD20 (protein found in B cells) along with antibody class switching (>75% Immunoglobulin G producing cells).

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Retrieved on: 
星期四, 五月 18, 2023
Waldenström macroglobulinemia, Partnership, City of Hope, Mayo Clinic, Employment, Birmingham School of Law, Malignancy, University, GBM, CD20, Fred Hutchinson Cancer Research Center, Neoplasm, Biotechnology, Lead, University of Massachusetts Chan Medical School, Translation, Sale, WM, Security, CAR, PSCA, CDMO, Hematological Cancer Research Investment and Education Act, City, Waldenström, Acquisition, CGMP, Patient, Cancer, XSCID, Birmingham, Ecosystem, Nationwide, Mustang, IND, DSM-IV codes, Leiden University, Vaccine, Bank, Pharmaceutical industry, Fine chemical, Greater Boston

WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.

Key Points: 
  • Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
  • Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
  • Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
  • I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.

Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023 - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bispecific monoclonal antibody, Monoclonal antibody, MOA, B-cell lymphoma, Therapy, CD3, CD20, Bi-specific T-cell engager, DLBCL, Roche, Cancer, Research, Antibody, Trial of the century, Patient, Location, Growth, Health Canada, Vaccine, Indication

The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bispecific Antibody Market Opportunity and Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • Insight On Bispecific Antibodies In Clinical Trials: > 700 Bispecific Antibodies
    Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
    The introduction of antibody-based therapeutics has been a game changer in the field of cancer therapy.
  • The continued expansion in research and development of antibody biologics has brought in the era of bispecific antibodies.
  • Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
    15.

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
星期四, 五月 11, 2023
Topotecan, GLP, Carcinoma, Abstract, Rituximab, LSD1, AACR, Cancer prevention, Follicular lymphoma, DLBCL, European Hematology Association, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Biotechnology, Clinical trial, Lenalidomide, NHL, CD20, American Association for Cancer Research, Cyclophosphamide, Salinicola salarius, SCLC, Bortezomib, Congress, Investigational New Drug, Hematological Cancer Research Investment and Education Act, Patient, Toxicology, Neoplasm, Ewing sarcoma, Research institute, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, News, Food, Cancer Prevention and Research Institute of Texas, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Video game

HOUSTON, May 11, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $9.3 million as of March 31, 2023, compared with $12.1 million as of December 31, 2022.
  • The decline reflects lower spending on seclidemstat in the 2023 quarter and one-time expenses of $2.0 million related to the purchase of the targeted protein degrader program in the 2022 quarter.
  • “In addition, Salarius continued to execute on plan during the first quarter of 2023 and recent weeks as we advanced the development of SP-3164, our targeted protein degrader.
  • Salarius will be participating in the 2023 BIO International Convention in Boston June 5-8, and the European Hematology Association 2023 Congress in Frankfurt, Germany June 8-11.

Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
星期二, 五月 9, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Gene, ACET, Bio, Design, CD20, NHL, Cancer, Holocene, Research and development, CAR, Transforming growth factor beta, CDMO, Patient, Administration, Cell, American Society of Gene and Cell Therapy, R, FDA, IND, Society, Safety, Pharmaceutical industry, Vaccine

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2023.
  • “We are excited about the continued clinical progress of our lead asset ADI-001,” said Chen Schor, President and Chief Executive Officer of Adicet.
  • The Company is preparing to initiate its first potential pivotal study with ADI-001 in the fourth quarter of 2023.
  • Financial Results for First Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.8 million for the three months ended March 31, 2023, compared to $13.5 million during the same period in 2022.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023

Retrieved on: 
星期二, 五月 9, 2023
Lymphoma, Amgen, Executive, Partnership, Drug development, Phenylalanine hydroxylase, Gene, CD19, Kite Pharma, Takeda, Lymphoid leukemia, CD20, Ornithine, PAH, Epithelium, Transposase, ESMO, Roche, Cancer, Breast, Oncology, Biomarker, Cell, AAV, American Society of Gene and Cell Therapy, PKU, Phenylalanine, Research and development, CAR, Development, Retirement, Genetic disorder, Novartis, Patient, Investment, SAN, Haemophilia, OTC, Mouse, Rare, European Society for Medical Oncology, Therapy, IND, News, Society, Pharmaceutical industry, Vaccine, Cryptocurrency, Research, Phenylketonuria

SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.  

Key Points: 
  • SAN DIEGO, May 9, 2023 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023.
  • The Company currently expects to present further clinical updates for the program at a medical meeting in 2023, subject to clearance with Roche.
  • Net loss was $38.8 million for the first quarter ended March 31, 2023, compared to $58.1 million for the same period of 2022.